



RECEIVED

1617

SEP 03 1999

PATENT

TECH CENTER 1600/2900

THE UNITED STATES PATENT AND TRADEMARK OFFICE

#2
AKD
9-8-99

Applicant(s): Achari et al.

Examiner: Unassigned

Serial No.: 09/334,537

Group Art Unit: Unassigned

Filed: June 16, 1999

Docket No.: 719-163

For: PHARMACEUTICAL FORMULATIONS
AND METHODS COMPRISING
INTRANASAL MORPHINE

Dated: August 27, 1999

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R. §1.56, Applicants submit herewith the following Information Disclosure Statement in accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

UNITED STATES PATENTS

<u>PATENTEE</u>	<u>PATENT NO.</u>	<u>ISSUE DATE</u>
Hussain	4,464,378	August 7, 1984
Morella et al.	5,202,128	April 13, 1993
Illum	5,629,011	May 13, 1997
Hill	5,880,132	March 9, 1999

I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to: Assistant Commissioner for Patents, Washington, D.C.

20231 on August 27, 1999
Dated: 8/27/99, J. M. Toris


NON-PATENT REFERENCES

Banker & Rhodes, Modern Pharmaceutics, Ch. 2, p. 40 (1979).

The above-listed references are also listed on Applicants' Substitute Form PTO-1449, which is attached to this Information Disclosure Statement.

As a result of this submission, Applicants respectfully submit that the application is in all respects in condition for examination on the merits.

Respectfully submitted,



Samir R. Patel
Reg. No. P-44,998
Attorney for Applicant

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, NY 11791

(516) 822-3550